Who
Kapil Dhingra
Director
Company insider
Files Form 4 as: Director, Black Diamond Therapeutics; Director, Replimune Group; Director, LAVA Therapeutics NV; Director, CARGO Therapeutics; Director, Five Prime Therapeutics; Director, Micromet.
In numbers
- Trades disclosed
- 48
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $1.9M
- Companies
- 6
- Companies where not an officer
- 6
- First trade
- 18 Feb 2009
- Last trade
- 26 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jun 2026filed 29 Jun 2026 | BDTX Black Diamond Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 26 Jun 2026filed 29 Jun 2026 | BDTX Black Diamond Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 1 Apr 2026filed 7 Apr 2026 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,500 at $0.00 | filing |
| 1 Apr 2026filed 7 Apr 2026 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,500 at $0.00 | filing |
| 9 Dec 2025filed 11 Dec 2025 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,169 at $0.00 | filing |
| 9 Dec 2025filed 11 Dec 2025 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code M | $5,5463,169 at $1.75 | filing |
| 9 Dec 2025filed 11 Dec 2025 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $33K3,169 at $10.40 | filing |
| 13 Nov 2025filed 17 Nov 2025 | LAVA Therapeutics NVoption or derivative | SEC FORM 4 Code D | —33,390 at $0.00 | filing |
| 13 Nov 2025filed 17 Nov 2025 | LAVA Therapeutics NV | SEC FORM 4 Code D | —30,000 | filing |
| 19 Aug 2025filed 19 Aug 2025 | CARGO Therapeuticsoption or derivative | SEC FORM 4 Code D | —25,000 | filing |
| 18 Jun 2025filed 20 Jun 2025 | CARGO Therapeuticsoption or derivative | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 12 Jun 2025filed 12 Jun 2025 | BDTX Black Diamond Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,550 at $0.00 | filing |
| 1 Apr 2025filed 3 Apr 2025 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 13 Feb 2025filed 18 Feb 2025 | LAVA Therapeutics NVoption or derivative | SEC FORM 4 Code A | —33,390 at $0.00 | filing |
| 6 Jun 2024filed 6 Jun 2024 | BDTX Black Diamond Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,550 at $0.00 | filing |
| 4 Jun 2024filed 6 Jun 2024 | CARGO Therapeuticsoption or derivative | SEC FORM 4 Code A | —11,871 at $0.00 | filing |
| 15 Apr 2024filed 17 Apr 2024 | CARGO Therapeuticsoption or derivative | SEC FORM 4 Code A | —49,265 at $0.00 | filing |
| 1 Apr 2024filed 3 Apr 2024 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 16 May 2023filed 17 May 2023 | BDTX Black Diamond Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,500 at $0.00 | filing |
| 1 Apr 2023filed 4 Apr 2023 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,200 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.